- $594.92m
- $591.86m
- $126.08m
- 62
- 29
- 44
- 41
Annual balance sheet for SurModics, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2020 September 30th | 2021 September 30th | 2022 September 30th | 2023 September 30th | 2024 September 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 61.1 | 38.9 | 19 | 45.4 | 40.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 16.2 | 22.9 | 24.2 | 23.9 | 23.3 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Current Assets | 86.6 | 70.3 | 57.6 | 86.7 | 81.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 32.6 | 32.5 | 30.8 | 29 | 28 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 169 | 195 | 158 | 186 | 179 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 18.9 | 29.8 | 32.1 | 24 | 20.5 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 37.7 | 54.5 | 50 | 65.8 | 59.7 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 131 | 140 | 108 | 120 | 119 |
| Total Liabilities & Shareholders' Equity | 169 | 195 | 158 | 186 | 179 |
| Total Common Shares Outstanding |